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Abstract: Neuropsychiatric symptoms are common in older adults with dementia and can be
associated with a rapid decline in cognitive and functional status. This article reviews the current
literature supporting the use of atypical antipsychotic medications in this population. Among the
currently available atypical antipsychotics, risperidone and olanzapine have been the most widely
studied in double-blind, randomized, placebo-controlled clinical trials. Despite the common use
of other atypical antipsychotic medications, their efficacy and safety in older adults with dementia
has not been as extensively studied. Some controversy surrounds the use of atypical antipsychotic
agents in older adults with the suggestion that they may increase the incidence of stroke or even
death. Despite the potential for increased risk of harm from the use of these medications, atypical
antipsychotics are often effective in treating troublesome neuropsychiatric symptoms refractory to
other treatments. Whenever possible, these atypical antipsychotic drug treatments should be
combined with non-pharmacological treatments to limit the need and dose of antipsychotic drugs
and constant monitoring for potential harms should be maintained. The choice of which atypical
antipsychotic agent can be guided by the nature and severity of the target symptom and the
medication least likely to cause harm to the patient.
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Introduction
Neuropsychiatric symptoms associated with dementia are common, and occur in the
majority of patients at some point during the course of their illness. Of those who
experience behavioral changes, many will experience multiple symptoms concurrently
(Sink et al 2004; Steinberg et al 2004). Some patients may experience changes in sleep
patterns, mood disturbance, or wandering, while others may develop agitation,
aggression or psychosis. In general, the severity of behavioral and psychological
symptoms of dementia (BPSD) seems to be positively correlated with the stage of
dementia; however, neuropsychiatric symptoms have been shown to be prevalent in
patients with mild cognitive impairment (MCI) and mild Alzheimer’s disease (AD)
(Hwang et al 2004). The severity of these symptoms can vary considerably from one
person to another. This variation in presentation may be related, in part, to the different
underlying types of dementia. For example, patients suffering from dementia with
Lewy bodies may be more prone to present with visual hallucinations, while patients
with frontotemporal dementia may be more likely to experience changes in personality
early on during the course of their illnesses. Nevertheless, even within a group of
patients with the same clinical diagnosis, considerable variability of symptom
presentation exists. In the later stages of dementia, all forms of neuropsychiatric
symptoms can be present regardless of underlying diagnosis.
The presence of neuropsychiatric symptoms of dementia is associated with an
increased level of caregiver burden and distress (Rinaldi et al 2005). A faster functional
decline is predicted by the presence of psychotic symptoms such as paranoid ideationNeuropsychiatric Disease and Treatment 2006:2(4) 522
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and hallucinations (Mortimer et al 1992). Even the presence of
milder neuropsychiatric disturbance may predict a poorer
outcome in patients with dementia. The presence of one or
more difficult behaviors has been associated with an increased
likelihood of institutionalization (Steele et al 1990;Yaffe
et al 2002). Many prior studies of the treatment of
neuropsychiatric symptoms in older adults with dementia
have not included measures of quality of life (Ballard and
Margallo-Lana 2004), yet reduction of troubling symptoms
would likely also lead to an improvement in quality of life
and improve outcomes.
Atypical antipsychotics are among the most commonly
prescribed medications used to treat mood and behavioral
disturbance associated with dementia. Despite their frequent
use, there is some controversy regarding the safety and efficacy
of atypical antipsychotics in this population. This article
reviews the currently available atypical antipsychotic agents
that have been studied in older adults with dementia, and
summarizes the evidence supporting their efficacy and the
potential concerns that have been raised about their safety.
Treatment of neuropsychiatric
symptoms
The management of BPSD has not been well standardized.
The heterogeneity of neuropsychiatric symptoms experienced
by patients with dementia may contribute to the lack of
consensus regarding the best way to treat these symptoms.
Clinicians often make the choice of treatment guided by the
underlying diagnosis of the type of dementia, the nature of
the target behavior being treated, and the tolerability of the
treatment being offered. Both non-pharmacological and
pharmacological treatments have been explored. Non-
pharmacological therapy can be cognitive, behavioral, or
environmental. Several non-pharmacological interventions
have all been shown to have a positive effect on
neuropsychiatric symptoms (Livingston et al 2005). Behavior
management therapies, specific types of caregiver and
residential care staff education, and possibly cognitive
stimulation appears to have lasting effectiveness. Treatments
centering on sensory stimulation have been shown to be
effective in reducing agitation and behavioral problems, but
the long-term effects are not clear. Most of these interventions
have not been studied in large randomized clinical trials.
Furthermore, the time commitment and training required to
administer non-pharmacological treatments can limit their
usefulness in certain situations; however, given that they are
generally safe and well tolerated, non-pharmacologic
interventions are largely considered to be first line therapy, or
at least adjunctive treatment, in all patients with BPSD.
Despite the use of non-pharmacological measures, use of
medications is often required for acute situations or refractory
symptoms. There are many medication options that have been
used for the treatment of BPSD. Among the medication options
available, antipsychotic therapy has been the most studied
(Sink et al 2005) and these medications are commonly
prescribed for the treatment of patients with dementia.
Antipsychotic medications are commonly divided into two
groups, the typical antipsychotics (sometime referred to as
conventional antipsychotics), and the newer atypical
antipsychotics (second-generation antipsychotics).
For many years, typical antipsychotic drugs were the most
commonly prescribed for the treatment of BPSD. Examples
of conventional antipsychotics include haloperidol,
perphenazine, chlorpromazine, and thioridazine. These
medications exert their primary mechanism of action by
blocking D2 receptors in the mesolimbic pathway of the brain.
Although there has been extensive experience with their use,
typical antipsychotics appear to be only modestly effective
and have potentially serious adverse effects that limit their
usefulness in older adults (Schneider et al 1990; Lanctot
et al 1998). Sedation, extrapyramidal symptoms (EPS) and falls
have been associated with the use of conventional
antipsychotics. Low potency typical antipsychotics (eg,
chlorpromazine) may be less appropriate for older adults with
dementia because of anticholinergic properties. A Cochrane
review showed that there is no evidence to support the use of
the low potency antipsychotic, thioridazine, in older patients
with dementia and that its use may expose patients to excess
side-effects (Kirchner et al 2000). Between 1964 and 2001, the
UK Committee on Safety of Medicines received 42 reports of
suspected heart rate and rhythm disorders associated with
thioridazine (Committee on Safety of Medicines/Medicines
Control Agency 2001). Thioridazine has recently been removed
from the Canadian market because of concerns regarding
its potential to induce cardiac arrhythmias (Health Canada
2005b).
Concerns about overuse of these medications led to the
Omnibus Budget Reconciliation Act (OMBRA) of 1987
(National Coalition for Nursing Home Reform, 1987) which
was US legislation that attempted to reduce psychotropic
medication prescriptions among residents of nursing homes.
Due to the potentially deleterious effects of these medications
on older adults, OBRA 87 recommended their use only as a
last resort for the management of behavioral problems, andNeuropsychiatric Disease and Treatment 2006:2(4) 523
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further required physicians to periodically reassess the need
for their use to prevent inappropriate long-term exposure to
these drugs. This legislation initially had a significant impact
on reducing the use of antipsychotic drugs in nursing homes
(Shorr et al 1994; Llorente et al 1998). The presumed benefit
of the legislation led others to explore how similar policies
might be adapted to other countries such as the United
Kingdom (Hughes et al 1999). There is a growing trend towards
moving away from legislated restrictions that focus on poor
prescribing practices and instead focusing on improving
quality of care for residents of nursing homes (Hughes and
Lapane 2005). Despite the call for improved education,
multidisciplinary collaboration, and attention to the needs
of nursing home residents, antipsychotic use is increasing.
One study from Canada (where no such legislation exists)
demonstrated that up to 24% of new residents in a nursing
home were started on an antipsychotic medication within
one year (Bronskill et al 2004). Despite the initial reduction
in use of these medications after introduction of OBRA 87, a
recent study demonstrated that the use of antipsychotic
medications among nursing home residents is increasing once
again, though the majority of nursing home residents are
now being prescribed atypical antipsychotics as opposed to
conventional agents (Briesacher et al 2005).
Atypical antipsychotics
Newer antipsychotic medications such as clozapine,
risperidone, olanzapine, quetiapine, ziprasidone and
aripiprazole have been collectively referred to as the atypical
antipsychotics. Like typical antipsychotics, atypicals block
D2 receptors along with other dopaminergic pathways, but
they also antagonize serotonergic receptors such as 5-HT2
(Meltzer 1989; Meltzer 1992). It is possible that serotonin
antagonism interacts to increase cortical dopamine release,
thus explaining their effect on the treatment of the negative
symptoms associated with diseases like schizophrenia
(Ichikawa et al 2001). The characteristics of how atypical
antipsychotics actually bind to the dopamine receptors may
also differentiate them from conventional agents (Kapur and
Seeman 2001; Strange 2001). Depending on the type of atypical
agent, there may be affects on muscarinic, alpha-adrenergic
or histaminic receptors. The actions of atypical antipsychotics
on these other receptors contribute to the differences in side
effect profile between agents. These medications are referred
to as a class due to the perception that they all share a lower
risk of EPS than older conventional antipsychotics like
haloperidol.
Clozapine
Clozapine (Clozaril
®) is a dibenzodiazepine derivative that
acts on dopamine binding to D1, D2, D3 and D5 receptors,
and it has a high affinity for D4 receptors. It also acts as an
antagonist against adrenergic, muscarinic, histaminergic and
serotonergic receptors. In contrast to conventional
antipsychotics, clozapine produces minimal to no elevation
in prolactin levels.
Introduced commercially in the United States in 1989,
clozapine was observed to cause fewer extrapyramidal
symptoms compared to conventional antipsychotic agents
like haloperidol. Although clozapine is considered to be
effective in treating refractory psychosis and suicidal
behavior in younger patients with schizophrenia, there is a
lack of information regarding its efficacy in treating older
adults with dementia. Much of the evidence to support the
use of clozapine in older patients has been gained from
studies that looked at the treatment of primary psychotic
disorders (Sajatovic et al 1997) or schizophrenia (Howanitz
et al 1999). Patients with Parkinson’s disease and psychosis
have also been shown to benefit from treatment with
clozapine (Ellis et al 2000; Klein et al 2003; Pollak et al
2004). There are no randomized controlled trials (RCT)
assessing the use of clozapine in dementia.
The potential for clozapine to induce neutropenia and the
emergence of alternative atypical antipsychotics has led to
limited use of this medication. Due to the risk of
agranulocytosis, clozapine users are required to perform
frequent monitoring of their white blood cell count weekly
for the first 6 months and then every other week for as long as
the patient takes this medication. Monitoring of the white
blood cell count is recommended to continue for 4 weeks
after discontinuation of therapy. Other adverse effects such
as sedation, hypersalivation, hypotension, cardiovascular
effects such as myocarditis, percarditis, and pericardial
effusion, and seizures limit its use even further.
Risperidone
Risperidone (Risperdal®) is a benzisoxazole derivative with
high affinity for 5-HT2 receptors, D2 receptors, and α1-
adrenergic receptors, and a lower affinity for other 5-HT
receptors, α2-receptors and histaminergic receptors. It is
thought to have little affinity for D1 receptors and no affinity
for muscarinic receptors.
Risperidone has been shown to benefit older adults with
primary psychotic disorder or schizophrenia (Sajatovic et alNeuropsychiatric Disease and Treatment 2006:2(4) 524
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1999; Davidson et al 2000), and of all the atypical antipsychotic
agents, risperidone has the most RCT evidence to support its
use in older adults with dementia (Lee et al 2004; Sink et al
2005). DeDeyn et al (1999) performed a
12-week trial in nursing home residents with dementia using
flexible doses of 0.5–4 mg/day of risperidone (mean dose
1.1 mg/day) versus placebo. The primary outcome was the
proportion of subjects achieving a greater than 30% reduction
from baseline to endpoint in Behavioral Pathology in
Alzheimer’s Disease Rating Scale (Reisberg et al 1987)
(BEHAVE-AD) total scores. For this outcome, risperidone was
not found to be superior to haloperidol or placebo. The study
reported a statistically significant difference between
risperidone and placebo on several of their secondary
endpoints. Katz et al ( 1999) performed a 12-week trial using
fixed doses (0.5, 1, 2 mg/day) of risperidone versus placebo
in nursing home residents with dementia. Subjects who
received 1 or 2 mg/day of risperidone showed significant
improvements compared to the placebo group on the
BEHAVE-AD as well as several secondary outcome measures.
Brodaty et al ( 2003) used flexible doses of risperidone (mean
0.95 mg/day) versus placebo in another study of nursing
home residents with dementia. The primary outcome measure,
the mean adjusted Cohen-Mansfield Agitation Inventory
(Cohen-Mansfield 1986; Cohen-Mansfield et al 1989)
(CMAI) total aggression scores, were significantly better with
risperidone as compared to placebo. BEHAVE-AD total scores
as well as several subscales of BEHAVE-AD and CMAI also
improved with risperidone.
The trials by De Deyn et al (1999) and Brodaty et al (2003)
(mean doses of approximately 1 mg/day of risperidone) did
not document significant differences in treatment-emergent
EPS compared to placebo, although EPS was more common
with haloperidol than risperidone. The Katz trial (Katz et al
1999) did find a dose-dependent increase in EPS with
risperidone that was significant for subjects receiving 2 mg/
day. Other adverse events were frequently documented in the
trials, but were similar with treatment and placebo. Somnolence
was more common with risperidone than placebo in the trial
by De Deyn et al (1999).
Risperidone can cause dose-dependent side-effects, so
minimizing the use of excessive doses is desirable. The more
common side-effects associated with risperidone use in
elderly patients are postural hypotension, sedation, and
EPS. These side effects (especially EPS) are dose-related,
suggesting a need for caution in increasing the dose
(Rochon et al 2005).
Olanzapine
Olanzapine (Zyprexa
®) is a thienobenzodiazepine derivative
with selective monoaminergic antagonism with high affinity
for 5-HT2A/2C, dopamine receptors D1-4, M1-5 muscarinic
receptors, H1 histaminergic receptors and α-1 receptors. It
binds with lesser affinity to GABAA, receptors and β
receptors. Olanzapine has been studied in the treatment of
older adults with schizophrenia or primary psychotic
disorders (Madhusoodanan et al 2000). In older adults with
dementia, Street et al (2000) studied olanzapine in fixed doses
(5, 10, 15 mg per day) versus placebo. The primary endpoint
of this study was the Neuropsychiatric Inventory-Nursing
Home (Cummings et al 1994) (NPI-NH) Core Total score, which
was used to classify patients as responders (greater than
50% reduction from baseline) versus non-responders. On
this measure, olanzapine 5 and 10 mg per day were superior
to placebo. The subjects receiving 15 mg/day of olanzapine
had worse outcomes compared to the subjects receiving 5
mg per day. It is probably advisable to use caution when
prescribing doses of olanzapine higher than 10 mg per day
in older adults with dementia. Another study performed by
De Deyn et al (2004) assessed fixed doses of olanzapine (1,
2.5, 5, and 7.5mg/day) versus placebo in the elderly with
dementia. No significant differences were seen between the
treatment groups on their primary measures of efficacy, the
NPI-NH Psychosis Total (delusions and hallucinations)
subscale or the Clinicians’ Global Impression of Change
(National Institute of Mental Health 1976) (CGI-C). There
were some positive benefits noted on certain secondary
measures for the 7.5 mg per day dose group compared to
placebo.
Street et al (2000) documented more somnolence and
abnormal gait among subjects receiving olanzapine versus
those on placebo. The trial by De Deyn et al (2004) did not
demonstrate any worsening of motor function or significant
anticholinergic effects on treatment with olanzapine.
Although increased weight, anorexia, urinary incontinence
were noted to be significantly different among the treatment
groups, they were not significant compared to the placebo
group. The placebo group had a statistically higher incidence
of abnormal behavior compared to the group receiving 7.5 mg
of olanzapine per day (3.9% versus 0.0%, p = 0.028).
Quetiapine
Quetiapine (Seroquel
®) is a dibenzothiazepine derivative
that has affinity for 5-HT1A/2 and dopamine D1-2 receptors. It
also has high affinity for histamine H1 receptors and α-1Neuropsychiatric Disease and Treatment 2006:2(4) 525
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receptors, and a lesser affinity for α-2 receptors. Quetiapine
has reportedly no appreciable effect on muscarinic or
benzodiazepine receptors. Quetiapine’s lack of muscarinic
receptor affinity and its lack of tendency to cause slowing on
encephalographic monitoring was thought to make it less
likely to cause cognitive impairment in older adults with
dementia (Byerly et al 2001); however, an RCT by Ballard
et al (2005) compared quetiapine (25–50 mg twice daily) to
rivastigmine (3–6 mg twice daily) or placebo. The group on
treatment with quetiapine did not show a significant
improvement on behavioral problems measured by the CMAI
compared to the other groups, and in fact demonstrated a
worsening in cognition as measured by the Severe Impairment
Battery (Saxton and Swihart 1989) (SIB). Other than the trial
by Ballard et al, there is very limited published RCT evidence
to support the use of quetiapine in older adults. It has been
best studied in patients with Parkinson’s disease (Fernandez
et al 1999).
Aripiprazole
Aripiprazole (Abilify
®) exhibits high affinity for dopamine
D2-3, 5-HT1A/2A, moderate affinity for D4, 5-HT2C/7, α-1
adrenergic and H1 receptors and muscarinic receptors.
Although approved for use in the United States and United
Kingdom, it is not available in Canada. Aripiprazole has been
reported to be minimally successful in treating patients with
probable Parkinson’s disease and drug-induced psychosis
(Fernandez et al 2004) In a population that included subjects
who were previously treated with other atypical
antipsychotics, only 2 out of 8 had resolution of their
psychosis, while 6 out of the 8 discontinued therapy. In a 10-
week, double-blind, placebo-controlled randomized trial in
older adults with Alzheimer’s disease, 208 community-dwelling
patients were randomized to treatment with either aripiprazole
(up to 15 mg per day) or placebo (De Deyn et al 2005). Those
subjects on treatment with aripiprazole (mean 10 mg per day)
showed no difference compared to placebo on the NPI-
psychosis subscale, but statistically significant improvement
from baseline on the Brief Psychiatric Rating Scale psychosis
and core subscales. Somnolence appeared more frequently in
patients on treatment with aripiprazole, but overall adverse
events appeared to be similar between treatment and placebo
groups.
Ziprasidone
Ziprasidone (Geodon®) exhibits high affinity for the D2-3,
serotonin 5-HT1A/1D/2A/2C and α-1 adrenergic receptors,
moderate affinity for histamine H1 receptors. Ziprasidone is
not approved for prescription in Canada or the United
Kingdom. There is very limited evidence to support the use of
ziprasidone in the elderly. The cardiac safety of intramuscular
ziprasidone in agitated elderly patients with dementia was
studied in a retrospective chart review (Greco et al 2005). In
small open label study, four patients with dementia and
agitation or psychosis showed improvement while receiving
oral doses of ziprasidone (20–160 mg per day) without any
evidence of problematic side-effects (Cole et al 2005).
Ziprasidone has been associated with prolongation of the QT
interval. Due to the risk of potentially fatal arrhythmias such
as torsade de pointes, it should not be used in patients with
QT prolongation or cardiac arrhythmias.
Other atypical antipsychotics
Sertindole, amisulpride, and zotepine are atypical
antipsychotic agents that have not been approved for use in
Canada or United States. Sertindole (Serdolect
®) is a
phenylindole derivative. Its activity appears to be specific
to D2, 5-HT2 and α-1 adrenergic receptors and largely
confined to the limbic dopamine system of the brain. The
availability of sertindole was voluntarily suspended by the
manufacturers following reports of cardiac arrhythmias and
sudden death associated with the use of this medication. It
was remarketed to the United Kingdom in 2002, but its use is
fairly restricted. Amisulpride (Solian
®) is a substituted
benzamide that binds selectively with a high affinity for
dopaminergic D2 and D3 receptors and lacks affinity for D1,
D4 and D5 receptor subtypes. It has reportedly no affinity for
serotonergic alpha-adrenergic, H1 histaminergic or
cholinergic receptors. Zotepine (Zoleptil
®) has a high affinity
for D1-2 recepetors and it also affects on 5-HT2A/2C/6/7
receptors. Due to the extremely limited experience with the
use of these medications and the potential for life-threatening
side-effects, the use of sertindole, amisulpride and zotepine
is not recommended in older adults with dementia.
Safety of atypical antipsychotics
Atypical antipsychotic agents are thought to cause less striatal
dopaminergic receptor antagonism compared to typical
antipsychotic medications (Ichikawa and Meltzer 1999).
Traditionally, use of atypical antipsychotics is thought to
have less risk of extrapyramidal symptoms (EPS) such as
Parkinsonism and tardive dyskinesia in older adults compared
to conventional antipsychotics (Jeste et al 1999, 2000). Based
on large retrospective cohort studies using administrativeNeuropsychiatric Disease and Treatment 2006:2(4) 526
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databases, there is some suggestion that the incidence of
Parkinsonism and tardive dyskinesia may be higher than
initially expected among users of atypical antipsychotics
compared to typical antipsychotics (Lee et al 2005; Rochon
et al 2005).
Patients with dementia with Lewy bodies or Parkinson’s
disease can be sensitive to treatment with antipsychotic
medications. Even though generally viewed to be safer in
these patients than conventional antipsychotics, patients with
dementia with Lewy Bodies or Parkinson’s disease can be
very sensitive to atypical antipsychotics as well (Ellis et al
2000; Morikawa Kishimoto 2002; Sadek and Rockwood
2003; Aarsland et al 2005). Among the atypical antipsychotic
agents, it is thought that quetiapine (Fernandez et al 2003),
and possibly clozapine are the most well tolerated in terms
of neuroleptic sensitivity in patients with either of these
disorders (Baskys 2004).
There is considerable concern about the potential
metabolic effects of antipsychotic medications including
atypical agents. Some evidence suggests that different
atypical antipsychotics have variable effects on weight gain,
insulin sensitivity and lipids. For instance, in younger
patients with schizophrenia, olanzapine was shown to be
associated with increased weight gain, and increases in
glucose and lipid metabolism (Lieberman et al 2005). In a
study of patients with a diagnosis of psychosis, olanzapine
and clozapine appeared to increase the risk of acquiring or
exacerbating type 2 diabetes mellitus while use of risperidone
did not (Gianfrancesco et al 2002). In 2003, the US Food and
Drug Administration (FDA) required all manufacturers of
atypical antipsychotics to include a warning about the risks
of hyperglycemia and diabetes. The use of olanzapine and
clozapine, but not risperidone, has been found to be associated
with hyperlipidemia in patients with schizophrenia (Koro et al
2002). A recent review of the atypical antipsychotics
quetiapine, olanzapine and clozapine, for patients with
schizophrenia suggested that they are associated with higher
risk of hyperlipidemia (Koro and Meyer 2005). While
schizophrenia itself may be associated with a metabolic
syndrome, there are a number of other factors including the
use of antipsychotic medications that can contribute (Thakore
2005). The effect of these medications in older adults with
dementia has not been as well studied. The few RCTs
performed assessing the use of atypical antipsychotics in the
elderly have been of short duration. This may not have allowed
sufficient time for potential metabolic effects of the medications
to develop. Yet, in a retrospective cohort study performed
specifically in older adults, there was no association
demonstrated between the new use of risperidone, olanzapine
or quetiapine and the development of diabetes mellitus
(Etminan et al 2003).
The potential association between atypical antipsychotics,
cerebrovascular events and deaths was first reported among
subjects receiving risperidone in a trial evaluating the use of
this drug in older adults with dementia published by Brodaty et
al (2003). In the risperidone group, 6 cerebrovascular adverse
events (CVAEs) were noted while none occurred in the placebo
group. All subjects who experienced a cerebrovascular event
had other risk factors for stroke including atrial fibrillation,
hypertension, prior transient ischemic attacks or strokes.
Health Canada and Janssen-Ortho released a statement
regarding the possible link between risperidone use and
CVAEs based on a meta-analysis of risperidone trials for
treatment of older adults with dementia. The FDA issued a
similar warning as well. More recently, pooled data from
clinical trials evaluating olanzapine have suggested that it
may also be associated with an increased risk of CVAEs in
patients with BPSD. The UK Committee on Safety of
Medicines (CSM) issued a warning advising that
risperidone and olanzapine should not be initiated to
manage BPSD (Duff & Committee on Safety of Medications
2004). The European Agency for the Evaluation of Medicinal
Products (EMEA) has issued warnings about the use of
olanzapine in elderly patients with dementia related
psychosis or behavioral disturbance (European Agency
for the Evaluation of Medicinal Products 2004). Despite
the potential link with an increased risk of CVAE in older
adults with dementia compared to placebo, a large
retrospective cohort study showed similar rates of CVAEs
between users of atypical antipsychotics compared to
conventional antipsychotics (Gill et al 2005).
Health Canada and the FDA issued public warnings based
on their own analysis of data from published and unpublished
RCTs showing increased mortality in older adults with
dementia receiving atypical antipsychotics (Health Canada
2005a; United States Food and Drug Administration 2005). In
their review of 17 RCTs involving risperidone, olanzapine,
quetiapine, and aripiprazole, the mortality rate was
approximately 1.7 times higher than placebo. The warnings
extend to all currently available atypical antipsychotics. A
meta-analysis of clinical trials assessing atypical antipsychotics,
also showed an increased risk of death in older adults with
dementia who were on treatment with an atypical antipsychotic
medication compared to placebo (Schneider et al 2005b).Neuropsychiatric Disease and Treatment 2006:2(4) 527
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Unfortunately, many of the RCTs evaluating these drugs have
not been published. In a meta-analysis by Schneider et al
(2005a) 9 of the 15 RCTs included in the meta-analyses had
not been published. The odds ratio by meta-analysis in this
study was 1.54 (95% CI 1.06–2.23, p = 0.02).
Antipsychotic medications including atypical
antipsychotics have the potential to cause fatal reactions
like neuroleptic malignant syndrome (NMS). Clinically, NMS
manifests as fever, rigidity, confusion, autonomic instability,
rhabdomyolysis and renal failure. Prompt recognition,
supportive treatment and close monitoring are essential for
patients with NMS  (Caroff et al 1998; Bhanushali and Tuite
2004).
Summary
Despite the controversy that surrounds the use of atypical
antipsychotic agents in older adults with dementia, these
medications are frequently being prescribed for the treatment
of neuropsychiatric disturbances. If initiation of therapy with
antipsychotic medication is considered, it should be only after
the potential benefits and risks are assessed. Given the serious
concerns about the safety of the use of atypical antipsychotic
medications in elderly patients with dementia, the use of non-
pharmacological approaches and/or alternative drug
treatments which might have a more favorable adverse
effect profile should be considered first. While atypical
antipsychotic medications may share common pharmacokinetic
characteristics, there are enough differences between them
to result in different efficacy and tolerability profiles. The
final choice of atypical antipsychotic agent should be guided
by the nature and severity of the target symptom being treated,
and the medication least likely to cause harm to the patient.
Whenever possible, these atypical antipsychotic drug
treatments should be combined with non-pharmacological
treatments to limit the need and dose of antipsychotic drugs.
After starting therapy with an atypical antipsychotic, constant
monitoring for potential harms should be maintained. Finally,
after the target symptoms have stabilized, a trial of tapering
and discontinuing the medication should be attempted if
possible.
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